

mChoice Consent to Screen (Aim 1 and 2)

We are conducting a study to improve the clinical experiences of gay, bisexual, and other men who have sex with men who are taking or starting HIV pre-exposure prophylaxis (PrEP). This study will increase our understanding of factors that influence PrEP choices. The study includes a 12-month period of monitoring PrEP use and an intervention based around a mobile phone app. Study assessments include completion of online surveys, entering information into the study app, sharing certain information from your PrEP medical care, and for some participants, a laboratory test on urine collected every 3 months. Some participants may be asked to complete an in-depth interview following the 12-month study period. Participants will also be asked to come in for an 18-month visit to complete a follow-up survey. Participants will be seen at a participating clinical site in New York City, NY and/or Birmingham, AL

Interested in joining the study?

If so, please answer the questions that follow to see if you are eligible to participate. The screening questions will take about 5-10 minutes to complete.

The questions will address topics like your age, sex, sexual partners, and whether you have been diagnosed with HIV. A risk of being screened is that the questions may make you uncomfortable. Please remember you can stop the screener at any time.

Another risk of screening is the possibility of your information being shared in a way that you did not intend. However, the study team has taken many steps to keep information secure, including using encryption and other data safety practices. Information you enter is confidential, will NOT be linked with your name, and will only be used for research purposes.

You will not directly benefit from being screened. If you are found eligible to enroll in the study, it is possible that you may benefit from enhanced support for using PrEP provided by the intervention. It is also possible you may not directly benefit from study participation, though your involvement would help us work toward our research goals to improve PrEP clinical care. You will receive your usual PrEP medical care regardless of your study participation. All study participants will receive financial incentives to support study participation.

If you have questions, or concerns, you may call the Principal Investigator, Dr. Rebecca Schnall at (212) 342-6886 or our study office number at (212) 305-8198. If you have questions or concerns about your rights as a research subject, you may contact the University of Columbia Institutional Review Board (IRB) at (212) 305-5883 or by email to irboffice@columbia.edu.

Do you consent to be screened for this study?